A phase II trial of PALI 2108
Latest Information Update: 03 Oct 2025
At a glance
- Drugs PALI 2108 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
Most Recent Events
- 03 Oct 2025 New trial record
- 05 Sep 2025 According to a Palisade Bio media release, the company is progressing toward Phase 2 IND submissions in Q1 2026.
- 07 Aug 2025 Accoridng to a palisade bio media release, company announces intention to submit phase II (Investigational New Drug) IND to USFDA for in the first half of 2026.